BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Exell S, Verdun E, Driebergen R. A new electronic device for subcutaneous injection of IFN-β-1a. Expert Review of Medical Devices 2014;8:543-53. [DOI: 10.1586/erd.11.29] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Fernández O, Arroyo R, Martínez-Yélamos S, Marco M, Merino JA, Muñoz D, Merino E, Roque A; RELOAD Study Group. Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis. PLoS One 2016;11:e0160313. [PMID: 27526201 DOI: 10.1371/journal.pone.0160313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
2 Moccia M, Palladino R, Russo C, Massarelli M, Nardone A, Triassi M, Lugaresi A, Brescia Morra V. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Expert Opin Drug Deliv 2015;12:1829-35. [PMID: 26371561 DOI: 10.1517/17425247.2015.1078789] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
3 Limmroth V, Gerbershagen K. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a. Expert Opin Drug Deliv 2014;11:1969-78. [PMID: 25255732 DOI: 10.1517/17425247.2014.943181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
4 Willis H, Webster J, Larkin AM, Parkes L. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device. Patient Prefer Adherence 2014;8:843-51. [PMID: 24966669 DOI: 10.2147/PPA.S54986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
5 Syed M, Rog D, Parkes L, Shepherd GL. Patient expectations and experiences of multiple sclerosis interferon β-1a treatment: a longitudinal, observational study in routine UK clinical practice. Patient Prefer Adherence 2014;8:247-55. [PMID: 24570582 DOI: 10.2147/PPA.S46421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
6 Lugaresi A. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opinion on Drug Delivery 2012;10:273-83. [DOI: 10.1517/17425247.2013.746311] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
7 D'Arcy C, Thomas D, Stoneman D, Parkes L. Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence 2012;6:55-61. [PMID: 22298944 DOI: 10.2147/PPA.S26250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]